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CLINICAL INVESTIGATION
Nifedipine reverses the abnormalities in [Ca21i and proliferation
of B cells from dialysis patients
JADWIGA M. ALExIEwIcz, MIROSLAW SMOGORZEWSKI, MOHAMMAD AKMAL, MARIUSZ KLIN,
and SHAUL G. MASSRY
Division of Nephrology and the Department of Medicine, The University of Southern Califorma, School of Medicine, Los Angeles, California, USA
Nifedipine reverses the abnormalities in lCa241i and proliferation of B
cells from dialysis patients. Both animals and patients with chronic renal
failure have impaired B cell function due, in part, to elevated levels of
cytosolic calcium ([Ca2ji). Treatment of HD patients with nifedipine has
normalized [Ca2]i of their polymorphonuclear leukocytes (PMNL) and
caused marked improvement in the phagocytic property of the PMNL.
This observation may have important clinical implications if this drug
exerts a similar effect on other cells such as B cells. We examined [Ca2]i,
proliferation of B cells in response to mitogen, the magnitude of the
PTH-induced inhibition of B cell proliferation, and the ATP content of
mononuclear cells in 11 hemodialysis patients treated with nifedipine, 12
patients without nifcdipine therapy and 11 normal subjects. Serum levels
of IgG was also measured in the two groups of patients. There were no
significant differences in the age, duration of hemodialysis, blood levels of
calcium, phosphorus or PTH (571 193 vs. 484 127 pg/mI) among the
two groups of patients. The hemodialysis patients without nifcdipine
therapy compared to those without nifedipine treatment have significantly
(P < 0.01) higher levels of [Ca2]i (120 1.9 nu vs. 94 2.2 nM), lower
ATP content of mononuclear cells (0.45 0.06 nmol/106 cells vs. 0.68
0.04 nmoles/106 cells), impaired proliferation (5.8 0.31 X IO cpm vs.
9.8 0.38 x iO cpm) and smaller inhibition of B cell proliferation by
PTH compared to those treated with nifedipine. The values in the patients
treated with nifedipine were still modestly but significantly different than
in normal subjects. The serum IgG levels of the patients without nifedipine
therapy (1210 71 mg/dl) were significantly lower than those of the
patients treated with nifedipine (1594 81 mgldl). Thus, the treatment of
hemodialysis patients with nifedipine produced marked and significant
improvement in the metabolic and functional parameters of B cells despite
no changes in blood levels of PTH. These data indicate that the calcium
channel blocker, nifedipine, interferes with PTH-induced rise in [Ca2]i of
B cells of hemodialysis patients and consequently improves their metab-
olism and function. These observations if confirmed in other human cells
may provide for a rational therapeutic approach to ameliorate the signs
and symptoms of uremia.
Humoral immunity is impaired in patients with chronic renal
failure. Indeed, the antibody response to viral antigen is reduced
[1], the number of total B cells may be decreased [2—4], and both
T cell-dependent and T-cell independent B cell proliferation are
impaired [5] in these patients.
Alexiewicz et a! [6] reported that the proliferation of B cells
from dialysis patients in response to Staphylococcus aureus Cowan
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I (SAC) or pokeweed mitogen was significantly lower than that
observed with B cells from normal subjects. Further, antibody
production (IgG, IgA and 1gM) by B cells in response to SAC and
pokeweed mitogen was impaired in dialysis patients [7]. These
derangements were attributed to the elevated blood levels of
parathyroid hormone (PTH) in dialysis patients in that PTH
produced similar derangements when applied to B cells from
normal subjects [6, 7].
PTH apparently exerts its deleterious effects on B cells by
increasing their cytosolic calcium ([Ca2]i) and/or by stimulation
of cAMP production by these cells. Indeed, [Ca2]i of B cells of
dialysis patients is elevated [7] and the hormone augments cAMP
production by these cells [6]. These effects are not surprising since
B cells have receptors for PTH [8—10].
It has been shown that calcium channel blockers reverse the
elevation in [Ca2]i in polymorphonuclear leukocytes (PMNL),
[11, 12], normalize their abnormal carbohydrate metabolism [11]
and significantly improve their phagocytic property [12]. It is,
therefore, possible to propose that calcium channel blockers may
also exert beneficial effect on B cell function.
The present study examined whether treatment of dialysis
patients with nifedipine restores basal levels of [Ca2]i of B cells,
their proliferation in response to SAC mitogen and their response
to PTH to normal.
Methods
At the time of the study our dialysis unit had 68 patients. All
nondiabetic dialysis patients treated with nifedipine (11 patients)
and an additional 12 nondiabetic patients who were not being
treated with nifedipine agreed to participate in the study. We also
had 11 healthy subjects to serve as controls. Table I provides the
characteristics and the biochemical parameters of the normal
subjects and of the two groups of patients studied. None of the
patients had evidence of systemic disease nor were they receiving
medications known to affect the immune response. There were no
significant differences between the various parameters among the
two groups of dialysis patients. The cause of renal failure in the
patients without nifedipine therapy was hypertension in 5, ob-
structive uropathy in 2, polycystic kidney disease in 1 and un-
known in 4. In those treated with nifedipine, the renal failure was
due to hypertension in 8, polycystic kidney disease in I and
unknown cause in 2. The patients were dialyzed with cellulose
acetate membrane (CA 210; Baxter Health Care Corp, Deerfield,
IL, USA) three times per week for three hours each session. The
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Table 1. Characteristics and biochemical parameters of normal subjects
and patients studied
Hemodialysis
Normal
subjects
Hemodialysis
patients
patients treated
with nifedipine
No. of patients 11 12 11
Age years 39 8.8 51 9.6 50 3.3
Sex (M/F) 4/7 8/4 4/7
Duration of HD months — 46 7.8 64 12.3
Plasma Ca mg/dl 9.3 0.29 8.9 0.27 8.8 0.31
Plasma P mg/di 3.72 0.17 6.2 0.41 6.5 0.42
Plasma Cr mg/dl 0.86 0.05 11.8 1.0 9.5 1.2
Serum PTH pg/mI <65 497 108 634 157
Hematocrit % > 38 33 0.9 33 1.4
Kt/V — 1.5 0.09 1.4 0.04
1,25(OH)2D3 dose ug/day — 0.35 0.04 0.44 0.04
Nifedipine dose mg/day — — 102 8.01 (60—120)
Duration of nifedipine — — 26.6 3.9 (13—48)
therapy month
Data are presented as mean 1 SE. Data in brackets represent range.
nifedipine used was long acting preparation (Procardia XL; Pfizer
Labs, NY, USA) and was given once daily. The relationship
between the ingestion of medication, the blood sampling and
dialysis procedure varied and was influenced by the timing of the
dialysis procedure: in six patients nifedipine was taken at 10:00
a.m. and after the dialysis procedure; in these patients the blood
samples were obtained between 5:00 and 5:30 a.m. In the other 5
patients the drug was ingested between 8:00 and 9:00 a.m. and
before the dialysis procedure; in these patients the blood samples
were obtained between 8:30 and 9:00 a.m. Blood samples were
obtained under sterile conditions before the dialysis session and
placed in vacutainers containing 20 U of preservative free heparin
(Gibco Laboratories, Grand Island, NY, USA) per each 1.0 ml of
blood.
Separation of B cells
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-hypaque centrifugation as described before [6]. B cells were
separated from PBMC using rosetting with immunomagnetic
beads coated with monoclonal antibody (mouse 1gM mAb) spe-
cific for the B cell restricted CD19 membrane antigen [Dynabeads
M-450 Pan B (CD19), Dynal Inc. Great Neck, NY, USA]. To
prevent attachment of phagocytic cells to Dynabeads, the latter
were first washed four times with RPM! 1640 (Gibco) containing
5% fetal calf serum (FCS) before their use utilizing magnetic
particle concentrator (Dynal MPC). Thereafter samples of IO
PBMC in I ml RPMI 1640 medium containing 5% FCS were
incubated with 50 .rl of Dynabeads for 20 minutes at 4°C. After
the incubation, the rosetted CD19 positive B cells were isolated by
placing the test tube in Dynal MPC for two to three minutes. The
supernatant containing non-rosetted (non B cells) cells, was
discarded and the rosetted cells were resuspended in 3 ml of 5%
FCS/RPMI 1640 medium. This procedure of removal of nonro-
setted cells was repeated five times. After the last washing, the
rosetted cells were resuspended in 100 jtl of 5% FCS/RPMI 1640
medium, and 20 il of detachment solution (DETACH a BEAD;
Dynal Inc.) was added to detach Dynabeads from B cells. The
detachment procedure was carried out for 60 minutes at room
temperature and the released beads were removed by placing the
test tube in the Dynal MPC for two to three minutes. The B cells
were then washed three times with 5% FCS/RPMI 1640 medium
to remove the remaining detachment solution. This separation
procedure resulted in > 95% pure B cell preparation as estimated
by FACSTAR flow cytometer (Becton Dickinson, Mountain
View, CA, USA) after staining with fluorescein conjugated anti-
CD2O (Leu 16; Becton Dickinson) monoclonal antibody.
Measurement of [Ca2 ]i in B cells
[Ca2]i in B cells was measured with Fura2-AM (Sigma Chem-
ical Co, St. Louis, MO, USA) using Perkin-Elmer fluorescence
spectrophotometer model LS5B (Perkin-Elmer Corp, Norwalk,
CT, USA) at excitation wavelengths of 340 nm and 380 nm and an
emission wavelength of 510 nm with a slit of 10 mm and 20 mm.
The details of this methodology was reported previously [7, 13].
Calculation of [Ca2]i was done using the Grynkiewicz equation
[14] and the dissociation constant for [Ca2]i was assumed to be
225 nmol/liter [14]. The reproducibility of the values of [Ca2 Ii in
B cells were tested by repeating the measurement in the same
subjects twice over different periods of time.
Assay of B cell proliferation
The proliferation assay was made as described by Shenker and
Matt [15]. Lymphocytes were cultured for five days in flat-
bottomed 96-well microplates (Linbro/Titertek; Flow Laborato-
ries, McLean, VA, USA) in a humidified environment of 37°C and
5% CO2 in a water-jacket incubator (Forma Scientific, Marrietta,
OH, USA). Each well contained 2 x io cells added to 100 pA of
culture medium, and 100 pJ of SAC. In parallel, similar cultures of
B cells were performed in the presence of 50 p1 of PTH delivering
1, 2 or 4 x i0 M PTH-[1-84]. In cultures without PTH or
mitogen, the desired amount of medium was added to reach the
final volume of 250 j.rl. Cell proliferation was measured by the
incorporation of [3H]thymidine (methyl-[3H]thymidine, specific
activity 6.7 Ci/mmol; ICN Radiochemical, Irvine, CA, USA),
which was added in the amount of 0.5 .tCi per well in 20 pJ of
medium for the last four hours of culture. The cultures were then
harvested onto glass-fiber filter paper by using an automatic cell
harvester (Cambridge Technology Inc., Cambridge, MA, USA).
The filters were placed in scintillation vials, air dried, and
quenched in Ecolite (JCN, Radiochemicals) before being counted
in a liquid scintillation counter (Model LS 7000; Beckman Instru-
ments, Palo Alto, CA) for the measurement of cell-bound radio-
activity. Each study was performed in three to four replicates, and
each well of these replicates was counted for three minutes. The
result of each study is the mean cpm of the three to four
replicates.
Assay of ATP in PBMC
The yield of pure B cells from each patients was not adequate
to measure both [Ca2]i and ATP content. We therefore mea-
sured ATP in PBMC, which represents both T and B cells. The
ATP content was measured according to the method reported by
Lundin et al [16]. An aliquot of 0.5 ml of 0.6 Mice-cold percholoric
acid was added to 5 x 106 PBMC in 0,5 ml of RPMI. After 10
minutes of extraction on ice, 62.5 i.tl of 2 M K2C03 was added, and
the mixture was centrifuged at 10,500 g for 10 minutes. The
supernatant was removed and immediately frozen with liquid
nitrogen and stored at —70°C. On the day of the assay, 50 pA of the
superuatant was added to 950 pl of 40 mt Tris buffer (pH 7.4),
and this mixture was diluted 20 times with distilled water. Samples
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Fig. 1. The relationships between the first and second measurement of
[Ca2]i of B cells performed in the same subjects over a wide range of basal
levels of [Ca2 ji. These measurements were made by the same investigator
(JMA) at 13 0.76 months apart. The solid line represents the actual
relationship (y = 16.5 0.8X, r = 0.947, P < 0.01). The interrupted line
represents the line of identity.
of 50 al were assayed for ATP by the firefly luminescence assay
with LAD 535 luminometer (Turner Design, Sunnyvale, CA,
USA). ATP standards were prepared with 40 mM Tris buffer,
distilled water and similar amounts of RPMI, perchloric acid, and
K2C03 as in PBMC preparation.
Biochemical measurements
The concentration of calcium in plasma was measured with a
Perkin Elmer spectrophotometer, and phosphorous and creati-
nine were estimated with an autoanalyzer (Technicon, Tarrytown,
NY, USA). Serum levels of PTH were determined using radio-
isotopic assay (Intact PTH; Nichols Institute Diagnostic, San
Juan, Capistrano, CA, USA; normal, 10 to 65 pglml). Serum levels
of IgG were measured in 9 patients treated with nifedipine and in
11 patients without nifedipine therapy using the standard labora-
tory techniques.
Reagents
Staphylococcus aureus Cowan I. SAC was obtained from Be-
thesda Research Laboratories Inc. (Gaithersburg, MD, USA). It
was prepared by diluting whole formalinized bacteria with culture
media and was used in a final concentration of 1:50,000 vol/vol,
which was established as optimal for our culture.
PTH. PTH-[1-84] was purchased from Sigma. It was dissolved in
100 m acetic acid and diluted with culture media to obtain the
desired concentration of I X iO, 2 X iO, and 4 X i0 M. The
solution was filtered for sterility through 0.22 jsm-pore-size ace-
tate membrane filters (Corning Glass Works, Corning, NY, USA)
and was used within one day.
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Fig. 2. Basal levels of [Ca2]i of B cells from normal subjects and
hemodialysis patients without treatment with nifedipine (HD) and those
treated with nifedipine (HD+NIF). Each datum point represents one
individual and brackets denote mean 1 SE.
Statistical analysis
Statistical analysis were made with ANOVA and the Bonfer-
roni-Dunn test for comparison between groups. Data are pre-
sented as mean SE.
Results
The repeated measurements of [Ca2]i in the same subjects
showed excellent correlation between two measurements sepa-
rated by 13 0.76 (9 to 17) months (Fig. 1). The basal
concentrations of {Ca2]i in B cells from dialysis patients without
nifedipine therapy (120 1.9 nM) were significantly (P < 0.01)
higher than those observed in B cells from normal subjects (Fig. 2;
80 1.9 nM). This difference represents a value of 50% above
normal. In the dialysis patients treated with nifedipine, the basal
levels of {Ca2Ji of B cells were 94 2.2 flM, a value significantly
lower than in patients without nifedipine therapy but still higher
(P < 0.01) than normal levels by about 18%.
Figure 3 provides the ATP content of PBMC in normal subject
and in the two groups of dialysis patients. The ATP contents of
PBMC from dialysis patients without nifedipine therapy (0.45
0.06 nmol/1 06 cells) were significantly (P < 0.01) lower than those
observed in normal subjects (1.0 0.05 nmol/106 cells). The
treatment of dialysis patients with nifedipine was associated with
a higher ATP content of their PBMC (0.68 0.04 nmol/106 cells).
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Normal HD HD+NIF
subjects
Fig. 3. A TP content of blood peripheral mononuclear cells from normal
subjects and hemodialysis patients without treatment with nifedipine (HD)
and those treated with nifedipine (lID +NIF). Each datum point represents
one individual and brackets denote mean isE.
This latter value is significantly (P < 0.05) higher than that in
dialysis patients without nifedipine therapy but lower than those
in normal subjects (P < 0.01).
SAC mitogen induced significant (P < 0.01) increments in B
cell proliferation in normal subjects and in both groups of dialysis
patients (Fig. 4). However, the increment in the dialysis patients
without nifedipine therapy (from 1.2 0.14 X iO to 5.8 0.31 X
iO cpm) was significantly (P < 0.01) smaller than in normal
subjects (from 1.8 0.19 x lO to 12.5 0.55 X iO cpm). The
treatment of dialysis patients with nifedipine was associated with
a significant improvement in B cell proliferation in response to
SAC (1.4 0.8 x iO to 9.8 0.34 x iO cpm). This change was
significantly (P < 0.01) higher than in the dialysis patients without
nifedipine but still lower (P < 0.05) than in normal subjects.
All concentrations of PTH produced significant inhibition of B
cell proliferation in normal subjects and in both groups of dialysis
patients (Fig. 5). However, the magnitude of the inhibition (%
inhibition) was greater (P < 0,01) in normal subjects than in
dialysis patients (Figs. 4 and 5). The inhibition by PTH of the
proliferation of B cells from dialysis patients without nifedipinc
therapy was smaller (P < 0.05) than that noted in dialysis patients
treated with nifedipine.
The serum concentrations of IgG in the dialysis patients
without nifedipine therapy (1210 71 mgldl) were significantly
(P < 0.01) lower than those in patients treated with nifedipine
(1594 81 mg/dl; Fig. 6).
flI
Normal subjects HD HD + NIF
Fig. 4. The effect of SAC mitogen on proliferation of B cells from normal
subjects and hemodialysis patients. Symbols are: () no mitogen; () SAC;(•) SAC + 4 X lO M PTH-(1—84). Each column represents mean value
and brackets denote 1 SE. SAC produced significant (P < 0.01) increments
in B cell proliferation in all groups (*P < 0.01 vs. no mitrogen). The
magnitude of the increment in the proliferation of B cells with SAC in
normal subjects and hemudialysis patients treated with nifedipine was
greater than in hemodialysis patients without nifedipine therapy (+P <
0.01 vs. HD). The inhibition of B cell proliferation by PTH was greater in
normal subjects and in patients treated with nifedipine than in patients
without nifedipine therapy (**P 1 0.01) versus HD).
Discussion
The results of the present study demonstrate that the abnor-
malities in B cell metabolism and function previously reported in
dialysis patients [6] are significantly ameliorated by the long-term
treatment of these patients with nifedipine. Indeed, this agent
restored toward normal the basal levels of [Ca2 ]i of B cells and
their proliferation in response to mitogen and resulted in a rise in
ATP content of PBMC as well. The improvement in B cell
proliferation was also associated with higher levels of serum IgG.
These observations are similar to those reported in regard to the
metabolism and function of PMNL of dialysis patients [11, 12].
Indeed, Hon et al [11] showed that treatment of dialysis patients
with verapamil reversed the abnormalities in their [Ca2]i and
carbohydrate metabolism, and Alexiewicz et al [12] found that
treatment of dialysis patients with nifedipine significantly amelio-
rated the elevation of basal levels of [Ca2]i of PMNL, and the
reduction in their ATP content and phagocytic ability. Thus, it
appears that calcium channel blockers exert a beneficial effect on
the derangements of function of B cells and PMNL as well.
The initial step leading to the elevation of [Ca2 ]i in chronic
renal failure is the PTH-mediated influx of calcium into the cells,
and in all cells PTH activates calcium channels inhibitable by
calcium channel blockers such as verapamil or nifedipine [17]. It
is not surprising, therefore, that treatment of dialysis patients with
nifedipine restored the levels of [Ca2]i in their B cells toward
normal. This agent apparently interfered with the action of the
high blood levels of PTH on B cells, It is of interest that nifedipine
failed to completely normalize [Ca2 ']i of B cells. This is probably
due to fact that, in many cells chronic excess of PTH enhances
calcium influx into cells through other types of calcium channels
and the hormone may mobilize calcium from intracellular stores
as well 1171. Such processes are not inhibited by nifedipine.
The improvements in B cell metabolism and function by
nifedipine were not due to differences in Kt/V, duration of
dialysis, hematocrit levels, treatment with 1,25(OH)2D3 or blood
levels of PTH. It is more likely that the effect of nifedipine is
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Fig. 5. The percent inhibition induced by various doses of PTH on the
SAC-induced proliferation by B cells from normal subjects and hemodialysis
patients. Each datum point represents mean value and brackets denote 1
SE. Symbols are: (0) normal subjects; (•) HD; (0) HD + NIF.
mediated through the ability of the agent to lower the basal levels
of [Ca2]i of the B cells toward normal,
A large body of evidence has accumulated indicating that the
elevation in basal levels of [Ca2]i of many cells from rats with
experimental chronic renal failure is responsible in major part for
the dysfunction of these cells [18]. In these studies, the normal-
ization of [Ca2]i of these cells by their treatment with verapamil
restored cell function [19-23]. It is plausible to propose, therefore,
that the improvement in the proliferation of B cells from the
dialysis patients treated with nifedipine is secondary to the
reduction in their basal levels of [Ca2]i by this drug. Support for
this notion comes from the data on the interaction between
[Ca2]i and the progression of cell-cycle. The progression from
Gi to S stage in B cells cycle depends on a decrease in [Ca2]i
[24], and it is possible that the sustained elevation in [Ca2]i of B
cells from dialysis patients interferes with this process and hence
with their proliferation, and the reduction in the levels of [Ca2Ii
by the treatment with nifedipine permits a better proliferative
response.
The above-mentioned discussion may imply that the PTH-
mediated rise in [Ca2]i of B cells is the single cause responsible
for B cell dysfunction in uremia. We emphasize that we do not
claim that this is indeed the case. We believe that other conse-
quences of uremia may also be operative.
Both in animals [18, 25] and in humans [6, 12] with chronic
renal failure is the ATP content of many cells reduced. This
phenomenon is also a consequence of the elevation in basal levels
of [Ca2]i [18]. The present study showed that ATP content of
another cell, PBMC, from dialysis patients is also reduced and
these values were restored toward normal by nifedipine therapy.
Although we did not measure the level of [Ca2Ii of PBMC, one
may assume that they are elevated since the [Ca2]i of both B
cells, as shown in the present study, arid of T cells [26] of
hemodialysis patients are elevated. ATP measures cell energy
state, and decreased ATP content of PBMC would reflect reduced
availability of energy in both T and B cells. Under such circum-
stance, B cell proliferation could be impaired.
We have previously shown that PTH inhibited in a dose
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Fig. 6. The serum levels of IgG in hemodialysis patients with and without
nifedipine therapy. Each datum point represents one patient and the
brackets denote mean I SE. The values between the two groups are
significantly different (P < 0.01).
dependent manner the proliferation of B cells from normal
subjects; this inhibitory effect was significantly blunted in B cells
from dialysis patients [6]. The present study confirms these
observations and extends them to show that the inhibitory effect of
PTH is restored toward normal in B cells from the dialysis patients
treated with nifedipine. Newer data on the interaction between
[Ca2]i and the mRNA of the PTH-PTHrP receptor in renal
failure may provide explanation for these observations [27-29].
Elevated levels of [Ca2]i down-regulate the mRNA of this
receptor in the kidney [27], the heart [28] and the liver [29] of
animals with renal failure. Normalization of the [Ca2Ji by
verapamil was associated with the return of the concentration of
the mRNA of this receptor toward normal despite renal failure
and elevated blood levels of PTH [28-30]. It is, therefore, reason-
able to suggest that the elevation in [Ca2]i of B cells of the
dialysis patients not treated with nifedipine down-regulated the
mRNA of their PTH-PTHrP receptor and consequently the
number of receptors was reduced, a situation that would lead to
impaired response to PTH. The restoration toward normal of
[Ca2]i of the B cells of the dialysis patients treated with
nifcdipine would increase the mRNA of the receptor, and im-
prove the response to PTH.
Dialysis patients have increased susceptility to infection [17,
18]. The United State Renal Data System showed that mortality
due to infection among dialysis patients aged 45 to 64 years is
16%. Both B cells and PMNL are critical for the defense of the
body against infection, and the beneficial effect of calcium channel
1254 Alexiewicz et at: Nifedipine and B cell fsinction
blockers on the metabolism and function of these cells could
provide a useful tool in the fight against infection in these patients.
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